Author

A. Yilmazer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 3 Bioengineering· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Approach:machine learning (classical)· 1 Organism:mouse· 1

Frequent Co-Authors

C. Gurcan· 3 shared G. Y. SUMMAK· 3 shared H. NAZIR· 3 shared K. C. AKCALI· 3 shared M. A. UNAL· 3 shared S. A. OZKAN· 3 shared A. OZKUL· 2 shared C. V. BITIRIM· 2 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

C. Gurcan

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Selective ablation of thymic and peripheral Foxp3+ regulatory T cell development

A. Yilmazer, D. M. Zevla, R. Malmkvist, C. A. Bello Rodriguez, P. Undurraga, E. Kirgin, M. Boernert, D. Voehringer, O. Kershaw, S. Schlenner, K. Kretschmer

This study shows that peripheral Foxp3+ Treg cells can compensate for the loss of thymic Treg cells, preventing autoimmunity, but thymic Treg cells are critical for controlling beta-cell autoimmunity in type 1 diabetes.

bioRxiv · Aug 4, 2023Immunology

Predicting the Reprogrammability of Human Cells Based on Transcriptome Data and SGD Classifier with Elastic-Net Regularization

G. Saygili, M. Turktas, C. Gurcan, L. G. Delogu, A. Yilmazer

This study predicts cell reprogramming outcomes using transcriptome data and an SGD classifier with Elastic-Net regularization, achieving 98% accuracy and 0.98 AUC.

bioRxiv · Jul 18, 2022 · PreprintBioengineering

Hemin shows antiviral activity in vitro, possibly through suppression of viral entry mediators.

M. A. UNAL, C. V. BITIRIM, J. SOMERS, G. Y. SUMMAK, O. BUL BESBINAR, E. KOCAKAYA, C. GURCAN, H. NAZIR, Z. B. Aksoy Ozer, S. A. OZKAN, S. BEREKETOGLU, A. OZKUL, E. DEMIR, K. C. AKCALI, A. YILMAZER

This study shows Hemin reduces SARS-CoV-2 infectivity in Vero E6 cells by decreasing TMPRSS2 and ACE2 expression.

bioRxiv · May 24, 2022 · PreprintPharmacology & Toxicology

Favipiravir, umifenovir and camostat mesylate: a comparative study against SARS-CoV-2

M. A. Unal, O. Besbinar, H. Nazir, G. Y. Summak, F. Bayrakdar, L. G. Delogu, T. Taskin, S. A. Ozkan, K. C. Akcali, A. Yilmazer

This study compares the antiviral effects of favipiravir, umifenovir, and camostat mesylate against SARS-CoV-2 using in silico and in vitro methods, finding that combination treatments are more effective than single drugs.

bioRxiv · Jan 11, 2022 · PreprintPharmacology & Toxicology

Ribavirin shows antiviral activity against SARS-CoV-2 and downregulates the activity of TMPRSS2 and the expression of ACE2 in vitro

M. A. Unal, C. V. Bitirim, G. Y. Summak, S. Bereketoglu, I. Cevher Zeytin, O. Besbinar, C. Gurcan, D. Aydos, E. Goksoy, E. Kocakaya, Z. Eran, M. Murat, N. Demir, J. Somers, E. Demir, , K. C. Akcali

bioRxiv · Dec 4, 2020Pharmacology & Toxicology